NCT06588868 Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
| NCT ID | NCT06588868 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Condition | Cutaneous T Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-02-27 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2025-02-27 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to describe the different approaches of systemic therapies for the treatment of Cutaneous T-cell Lymphoma in real world setting.
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of CTCL according to the EORTC 2017 update criteria1. * Age ≥18 years. * Have received first dose of a systemic therapy, lasted at least 3 months, between 1 January 2016 and 31 December 2023. * Availability of complete medical records in order to provide protocol required variables * Signed written informed consent. Exclusion Criteria: * Patients not meeting the above-mentioned inclusion criteria. * Refuse to sign a written informed consent.
Contact & Investigator
Pietro Quaglino, MD
PRINCIPAL INVESTIGATOR
SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino
Frequently Asked Questions
Who can join the NCT06588868 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cutaneous T Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06588868 currently recruiting?
Yes, NCT06588868 is actively recruiting participants. Contact the research team at startup@filinf.it for enrollment information.
Where is the NCT06588868 trial being conducted?
This trial is being conducted at Ancona, Italy, Bari, Italy, Bari, Italy, Bologna, Italy and 11 additional locations.
Who is sponsoring the NCT06588868 clinical trial?
NCT06588868 is sponsored by Fondazione Italiana Linfomi - ETS. The principal investigator is Pietro Quaglino, MD at SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino. The trial plans to enroll 400 participants.